There are currently 1474 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892
Recruiting
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Parkland Health and Hospital System, Dallas, Texas +6 locations
Conditions: Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
Register for Updates
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
NCT05318105
Recruiting
The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop diuretics in patients with worsening heart failure (HF) and fluid overload.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Baylor Scott & White Research Institute, Dallas, Texas
Conditions: Heart Failure (for Example, Fluid Overload), Heart Failure, Fluid Overload
Register for Updates
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
NCT03418961
Recruiting
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Register for Updates
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT04227847
Recruiting
This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for participants with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and if it works for AML and MDS. A side effect is anything the drug does besides treating cancer. This study will have seven groups or "parts." * Part A will find out how much SEA-CD70 should be given to participants * Part B will use the dose fou... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas, Texas +1 locations
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Register for Updates
DBS for Depression
NCT03437928
Recruiting
The goal of the study is to address the unmet need of TRD patients by identifying brain networks critical for treating depression and to use next generation precision DBS with steering capability to engage these targeted networks. The study's goal will be achieved through 3 specific aims: 1. Demonstrate device capability to selectively and predictably engage distinct brain networks 2. Delineate depression-relevant networks and demonstrate behavioral changes with network-targeted stimulation 3.... Read More
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
05/12/2025
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Major Depressive Disorder
Register for Updates
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
NCT04375813
Recruiting
eRapa (encapsulated rapamycin) will be investigated for secondary prevention in patients with diagnosed non-muscle invasive bladder cancer (NMIBC) through a phase II double-blind randomized controlled trial of long-term (one year) prevention with eRapa versus placebo. The primary hypothesis is that eRapa decreases the risk of cancer relapse for patients with NMIBC. Secondary hypotheses are that eRapa can improve certain immune parameters and improve cognition and physical function without advers... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Non-muscle Invasive Bladder Cancer
Register for Updates
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials
NCT06445322
Recruiting
This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
05/12/2025
Locations: Retina Foundation of Texas, Dallas, Texas
Conditions: Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration
Register for Updates
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
NCT06855329
Recruiting
This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis (PPF) classification and establish PPF incidence for key ILD subtypes. Additional exploratory objectives are to 1) Prospectively validate a novel PPF classifier and assess performance durability over... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/12/2025
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia
NCT05816343
Recruiting
Type I hyperlipoproteinemia (T1HLP, also known as familial chylomicronemia syndrome or FCS) is a rare diseasewhere the blood triglycerides (fats) are very high. It is caused by lack of certain enzymes and proteins in the bodythat are important in disposing circulating fats from blood. Treatment of T1HLP patients who have very high levels of blood fats (≥ 1,000 mg/dL) is challenging as conventional triglyceride-lowering medications, such as fibrates and fishoil, are ineffective. The purpose of t... Read More
Gender:
ALL
Ages:
8 years and above
Trial Updated:
05/09/2025
Locations: UT southwestern Medical Center, Dallas, Texas
Conditions: Type 1 Hyperlipoprotenemia
Register for Updates
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center, Dallas, Texas +1 locations
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
NCT01668082
Recruiting
The study is designed to use infusion of a non-radioactive, naturally occurring isotope of glucose (13C) in patients undergoing surgical resection for a newly identified brain mass to obtain the metabolic phenotype of the tumor, and correlate it with the histopathological diagnosis. In each patient, 13C NMR spectral analysis of tumor extracts will be obtained after intraoperative infusion of \[U-13C\]glucose or \[1,2-13C\]glucose. Whenever feasible, patients will undergo 3 preoperative imaging s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Brain Mass
Register for Updates
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
NCT06634394
Recruiting
A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Acute Myeloid Leukemia (AML)
Register for Updates